CKD-843
A long-acting dutasteride injection intended to replace the daily tablet with a quarterly dose.
- Developed by
- Chong Kun Dang Pharmaceutical
- Current phase
- Phase 3
- Indications
- Androgenetic alopecia
- Also known as
- CKD-843 A, CKD-843-R, CKD843
- Last public activity
- April 2025
- Record confidence
- Medium
Large confirmatory trials. The last step before filing.
How it is meant to work
Reported by the sponsor as a depot formulation of dutasteride, the same dual 5-alpha-reductase inhibition already used orally for hair loss in South Korea and Japan. What is being tested is the delivery, not the mechanism.
Why it matters
Adherence is the quiet failure mode of every daily antiandrogen, and a quarterly injection addresses it directly. The phase III enrolled 288 men and compares two dose levels against both placebo and oral dutasteride, which is the right comparator and a more demanding one than placebo alone. Primary completion is December 2026.
Development history
- Phase 1Phase 3
First Phase 3 trial on record: NCT06916793 — A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
ClinicalTrials.gov ↗ - Phase 1
First Phase 1 trial on record: NCT04805606 — A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Chong Kun Dang Pharmaceutical · n=288 · April 2025
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
Chong Kun Dang Pharmaceutical · n=41 · November 2022
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
Chong Kun Dang Pharmaceutical · n=40 · April 2021
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.